Key Points
- Guardant Health director Musa Tariq sold 116 shares on June 16 at an average price of $130.19, totaling about $15,102. The sale was made under a pre-arranged Rule 10b5-1 plan.
- After the transaction, Tariq still directly owned 8,796 shares valued at about $1.15 million, representing a 1.30% reduction in his position. He has also sold shares in prior months at lower prices.
- Wall Street remains largely bullish on GH, with an average rating of “Moderate Buy” and an average price target of $141.95. The stock was trading near its 52-week high, and institutional investors own about 92.6% of the company.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Musa Tariq sold 116 shares of the company's stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $130.19, for a total value of $15,102.04. Following the completion of the sale, the director directly owned 8,796 shares of the company's stock, valued at $1,145,151.24. The trade was a 1.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Musa Tariq also recently made the following trade(s):
- On Monday, May 18th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $95.96, for a total value of $11,131.36.
- On Thursday, April 16th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $84.83, for a total transaction of $9,840.28.
- On Wednesday, March 18th, Musa Tariq sold 348 shares of Guardant Health stock. The shares were sold at an average price of $88.09, for a total transaction of $30,655.32.
Guardant Health Trading Down 1.9%
NASDAQ GH opened at $127.34 on Wednesday. The stock has a market cap of $16.89 billion, a P/E ratio of -37.56 and a beta of 1.61. The company's fifty day simple moving average is $104.90 and its 200-day simple moving average is $102.36. Guardant Health, Inc. has a 52 week low of $40.35 and a 52 week high of $135.00.
Wall Street Analyst Weigh In
A number of research firms have commented on GH. Robert W. Baird started coverage on shares of Guardant Health in a research note on Tuesday, February 17th. They set an "outperform" rating and a $120.00 price objective on the stock. Canaccord Genuity Group upped their target price on shares of Guardant Health from $125.00 to $135.00 and gave the company a "buy" rating in a research note on Friday, February 20th. TD Cowen reiterated a "buy" rating on shares of Guardant Health in a research note on Thursday, May 21st. Royal Bank Of Canada initiated coverage on Guardant Health in a report on Thursday, June 11th. They set an "outperform" rating and a $185.00 target price on the stock. Finally, The Goldman Sachs Group assumed coverage on Guardant Health in a report on Friday, June 5th. They issued a "buy" rating and a $165.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Guardant Health presently has an average rating of "Moderate Buy" and an average target price of $141.95.
View Our Latest Report on Guardant Health
Hedge Funds Weigh In On Guardant Health
Large investors have recently bought and sold shares of the business. V Square Quantitative Management LLC acquired a new stake in shares of Guardant Health during the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC bought a new stake in Guardant Health in the fourth quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Guardant Health during the fourth quarter worth about $31,000. Elyxium Wealth LLC acquired a new position in Guardant Health during the 4th quarter valued at about $35,000. Finally, Parallel Advisors LLC increased its stake in shares of Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company's stock valued at $36,000 after purchasing an additional 219 shares during the period. Institutional investors own 92.60% of the company's stock.
Guardant Health Company Profile
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
